Integrative Treatment and Management for Hyperparathyroidism

Learn about holistic approaches to hyperparathyroidism integrative treatment that promote overall well-being and balance

Educational Abstract: Integrative Insights on Primary Hyperparathyroidism, Quality of Life, and Multidisciplinary Care

Welcome to this comprehensive educational guide on hyperparathyroidism, a condition often characterized by the overproduction of parathyroid hormone (PTH), which plays a crucial role in regulating calcium levels in our blood and bones. In this post, we will embark on a detailed, evidence-based journey to understand the intricacies of hyperparathyroidism, starting with its primary symptom: hypercalcemia, or elevated calcium levels. I will explain how calcium, vitamin D, and PTH regulate human physiology; how laboratory and imaging modalities clarify diagnosis; and how surgical and medical strategies are selected, sequenced, and personalized. We will delve into the different types of hyperparathyroidism—primary, secondary, and tertiary—and discuss the clinical criteria that guide treatment decisions, particularly the indications for surgery, which remains the only definitive cure.
This post will also cover medical management options, including medications like Cinacalcet (Sensipar) and bisphosphonates, and highlight the importance of an integrated, multidisciplinary approach. I will explain how our unique practice model at the Injury Medical Clinic PA in El Paso, Texas, brings together the expertise of Dr. Maria Guadalupe Cardenas, MD, a highly experienced board-certified internist serving as our Medical Director, with my own background in chiropractic, functional medicine, and as a Family Nurse Practitioner. This collaborative framework allows us to provide holistic, evidence-based care that addresses the musculoskeletal, metabolic, and systemic aspects of hyperparathyroidism. Join me as we explore the latest findings from leading researchers, translate them into actionable clinical protocols, and share real-world observations from my practice to turn “calcium chaos” into clarity.

Calcium Chaos Made Understandable: A First-Person Educational Journey

I have spent decades observing how subtle shifts in calcium physiology reverberate through the nervous system, musculoskeletal integrity, kidney function, and cognitive well-being. What may appear as a simple “high calcium” on a routine lab can conceal years of bone remodeling imbalance, silent nephrolithiasis, accelerating vascular calcification, and progressive neurocognitive changes. When I first encountered patients with unexplained fatigue, recurrent musculoskeletal pain, and vague gastrointestinal symptoms, I noticed a pattern—”normal” ranges did not explain their day-to-day experience. That realization led me to dig into the physiology behind calcium chaos and build a multidisciplinary pathway with medical, functional, and chiropractic expertise, guided by rigorous research.
In this educational post, I will:

Define primary hyperparathyroidism and differentiate it from secondary and tertiary forms.
Explain the physiological roles of calcium, vitamin D (D3 and D2), PTH, and phosphorus.
Discuss laboratory tests including serum calcium, albumin-adjusted calcium, ionized calcium, PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, urinary calcium excretion, and phosphorus.
Review imaging modalities: neck ultrasound, sestamibi scintigraphy, 4D-CT, and MRI.
Outline medical management strategies, including hydration, antiresorptives, and cinacalcet.
Detail indications and protocols for parathyroidectomy, with modern minimally invasive methods.
Illustrate how integrative chiropractic care fits into comprehensive management—addressing posture, pain, fracture prevention, and rehabilitation.
Integrate functional medicine frameworks for root-cause investigation, including nutrition, microbiome, and stress physiology.
Present personal injury considerations and case-style narratives connecting physiological insights to clinical decisions.
Cite leading researchers, synthesize current literature, and provide APA-7 in-text citations with linked references.

My goal is to make this journey readable and relatable: to take you step-by-step across the terrain of hyperparathyroidism and its practical, integrative care.

Meet Our Collaborative Team: Internal Medicine and Chiropractic in an Integrative Clinic

At the Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, we have cultivated a unique, multidisciplinary environment dedicated to providing comprehensive and patient-centered care. A cornerstone of our practice is the collaborative relationship between me, Dr. Alex Jimenez, and our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with an impressive career spanning over 40 years (NPI #1164426749, Texas MD License #J2933). Her vast experience and deep understanding of internal medicine provide the essential medical oversight that underpins our integrative model.
This partnership allows us to blend the best of multiple disciplines. My expertise as a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse (APRN) specializing as a Family Nurse Practitioner (FNP-BC), combined with advanced certifications in functional and integrative medicine, focuses on the body’s structure, function, and underlying metabolic pathways. Dr. Cardenas’s role as the supervising physician is crucial. She provides the medical direction necessary to diagnose and manage complex internal conditions like PHPT, prescribe medications, order labs and imaging, and ensure that all aspects of our patients’ care meet the highest medical standards. This setup is common in leading-edge integrative and injury care clinics, where the synergistic expertise of a Medical Doctor (MD) and a Doctor of Chiropractic (DC) creates a powerful therapeutic alliance.
Together, our team integrates:

Medical Diagnosis and Management (Dr. Cardenas): Providing primary medical assessment, oversight of complex endocrine conditions, and prescription management.
Chiropractic Care (Dr. Jimenez): Focusing on spinal and joint alignment, nervous system function, and biomechanical health to reduce pain and improve mobility.
Functional Medicine (Dr. Jimenez): Investigating the root causes of chronic illness by analyzing genetics, lifestyle, and environmental factors to create personalized health strategies.
Rehabilitation and Personal Injury Care: Developing customized programs to help patients recover from injuries, restore function, and prevent future issues.
Nutritional and Lifestyle Counseling: Guiding patients toward optimal health through diet, exercise, and stress management techniques.

This integrated model ensures that when a patient presents with a condition like hyperparathyroidism, we can address it from multiple angles. While Dr. Cardenas oversees the medical diagnosis and management of the endocrine disorder, I can implement supportive chiropractic and functional medicine protocols to manage associated symptoms like bone pain, muscle weakness, and fatigue, and to optimize overall metabolic health. This holistic approach empowers our patients on their journey to wellness.

The Historical Perspective: Early Recognition and Surgical Milestones

The first diagnosis of hyperparathyroidism was documented in 1926 by Dr. Eugene Dubois, whose patient, Captain Charles Martel, suffered progressive skeletal disease and repeated surgeries until a parathyroid adenoma was discovered. His case, dramatic and tragic, foreshadowed the intimate link between parathyroid pathology and bone. Historically, before the widespread use of routine biochemical screening that began around 1970, this condition was known by the memorable triad of “bones, stones, and abdominal groans.” Patients were often symptomatic, presenting with bone pain, kidney stones, and gastrointestinal issues. Today, surgical finesse and biochemical understanding enable earlier identification and curative procedures, reducing the severe bone and renal complications that tormented early patients.

Identifying High Calcium: The First Step in the Diagnostic Journey

When we begin to investigate conditions like hyperparathyroidism, our journey often starts with a simple, yet profoundly important, lab finding: hypercalcemia, or an elevated level of calcium in the blood. While hyperparathyroidism is a primary suspect, it is by no means the only cause. As a clinician, my first responsibility is to consider a broad differential diagnosis to ensure we are not overlooking other serious conditions. High calcium levels, particularly those exceeding 12 mg/dL, demand a thorough and systematic evaluation.
Here are some of the critical conditions we must consider when a patient presents with hypercalcemia:

Hypercalcemia of Malignancy: This is one of the most serious considerations. Certain cancers can produce a substance called parathyroid hormone-related peptide (PTHrP), which mimics the action of PTH and causes calcium to be released from the bones. Other malignancies, such as multiple myeloma or cancers that have metastasized to the bone, can directly destroy bone tissue, releasing calcium into the bloodstream.
Vitamin D or Vitamin A Toxicity: In our modern world of supplements, it’s not uncommon for individuals to overdo it. Excessive intake of vitamin D can increase calcium absorption from the gut, resulting in hypercalcemia. Similarly, though less common, vitamin A toxicity can also affect bone metabolism and elevate calcium levels.
Milk-Alkali Syndrome: This condition arises from the ingestion of large amounts of calcium and absorbable alkali, typically from over-the-counter antacids. I recall a recent case in our clinic that perfectly illustrates this point. A patient presented with significantly high calcium levels. During our detailed consultation, a crucial part of the functional medicine approach, we explore every aspect of a patient’s lifestyle, including supplements. When I asked her specifically about any over-the-counter products she was taking, she mentioned using Tums for indigestion. The follow-up question is always about quantity. When I asked how many she was taking, she revealed she was consuming about thirty Tums per day. This crucial piece of information immediately pointed us toward the cause of her hypercalcemia. It underscores the absolute necessity of asking detailed, quantified questions during the patient history.
Other Potential Causes: The list of possibilities extends further. We also consider:
- Prolonged Immobilization: Patients who are bedridden for long periods can experience increased bone resorption, leading to a release of calcium.
- Hyperthyroidism: An overactive thyroid gland can accelerate bone turnover and cause mild hypercalcemia.
- Granulomatous Diseases: Conditions like sarcoidosis or tuberculosis (TB) can lead to the formation of granulomas, which can activate vitamin D and subsequently raise calcium levels.
- Medications: Certain drugs like thiazide diuretics and lithium can disrupt calcium homeostasis.
- Adrenal Insufficiency: A deficiency in adrenal hormones can sometimes be associated with hypercalcemia.
- Total Parenteral Nutrition (TPN): Patients receiving all their nutrition intravenously can sometimes develop imbalances in their calcium levels.

Understanding this broad landscape is the first step in a precise and effective diagnostic process.

Clinical Pearls for Navigating an Elevated Calcium Result

When routine lab work reveals an elevated serum calcium level, it’s essential not to jump to conclusions. A calm, methodical approach is key. Here are some “clinical pearls”—practical steps and considerations—that I follow in my practice to navigate this finding effectively.

The First Step: Recheck and Confirm

The very first action I take when I see an isolated elevated serum calcium result is simple: recheck it. Lab errors can happen, and transient fluctuations can occur. I will have the patient come back for a repeat blood draw, ideally under controlled conditions (e.g., fasting). If the repeat test comes back normal and there are no other red flags in the patient’s history or exam, we can often monitor the situation. I might say, “Let’s move on for now, but we’ll keep an eye on this in future lab panels.” If the elevation reappears on a subsequent test down the line, then a more thorough investigation is warranted. However, if a single repeat test normalizes, we can often avoid an unnecessary and potentially costly workup.

The Second Step: Deepen the Investigation

If the repeat calcium level is also elevated, our investigation deepens. This is the point where we need more data to understand the underlying physiology. The next logical and crucial test to add is a parathyroid hormone (PTH) level. This single test is the most important differentiator. The relationship between calcium and PTH tells us a story:

High Calcium + High PTH: This combination strongly suggests primary hyperparathyroidism, where the parathyroid glands are autonomously overproducing the hormone.
High Calcium + Low PTH: This pattern indicates that the parathyroid glands are functioning correctly—they are trying to shut down production in response to the high calcium. This points us toward other causes, such as malignancy or vitamin D toxicity.

Considering Ionized Calcium

You might also consider ordering an ionized calcium level. Total serum calcium, which is what is measured in a standard metabolic panel, is about 50% bound to proteins, primarily albumin. The other 50% is the “free” or “ionized” calcium, which is the biologically active form. Ionized calcium directly interacts with the calcium-sensing receptor (CaSR) on parathyroid chief cells, guiding PTH secretion. Changes in albumin levels can affect the total calcium measurement without changing the active ionized calcium. For instance, in a dehydrated patient with high albumin, the total calcium might appear falsely elevated.
We often use a formula to calculate a “corrected calcium” based on the albumin level. However, ordering a direct ionized calcium test can sometimes provide a more accurate picture, especially when albumin is abnormal, acid-base status is unstable, or when clinical symptoms diverge from total calcium readings. It’s important to remember, though, that in a relatively healthy individual with a normal acid-base status, the corrected calcium is often sufficient.

The Physiology of Calcium: Roles, Regulation, and Resonance

Calcium is more than a bone mineral; it is a signaling ion orchestrating countless processes.

Cardiac conduction: Calcium influx drives the plateau phase of action potentials; abnormalities can precipitate arrhythmias.
Neuromuscular function: Calcium binds troponin C, enabling muscle contraction. Hypercalcemia can alter excitability, causing weakness or fatigue.
Neurotransmission: Presynaptic calcium influx triggers synaptic vesicle release; dysregulation affects cognition and mood.
Coagulation: Calcium (Factor IV) is essential for activating various clotting cascades.
Bone remodeling: Calcium combines with phosphate in hydroxyapatite; osteoclast and osteoblast balance hinges on PTH and vitamin D.

Serum calcium exists in three fractions:

Protein-bound (mostly to albumin): Not bioactive; shifts with albumin changes.
Complexed (bound to anions such as citrate, phosphate).
Ionized (free): The bioactive fraction; tightly regulated, it reflects the true physiologic impact.

Symptoms of Hypercalcemia: Thresholds and Clinical Nuance

Mild elevations (around 10–11 mg/dL): Often asymptomatic or subtle—fatigue, constipation, mild mood changes.
Moderate elevations (>11 mg/dL): Nausea, abdominal pain, anorexia, cognitive changes, dehydration, decreased exercise tolerance.
Severe elevations (≥12–14 mg/dL): Neurocognitive impairment, acute kidney injury, arrhythmias, altered mental status; can become life-threatening.

In emergency settings, patients may be obtunded with acute renal compromise. Rapid stabilization—IV hydration, loop diuretics (after volume repletion), calcitonin, and consideration of bisphosphonates—is essential. Our integrated team prioritizes assessment of the underlying cause: PHPT, malignancy, granulomatous disease, thyrotoxicosis, drug-induced hypercalcemia, immobilization, vitamin A toxicity, and milk-alkali syndrome.

Understanding the Types of Hyperparathyroidism: Primary, Secondary, and Tertiary

Hyperparathyroidism is not a single entity. It is categorized into three distinct types—primary, secondary, and tertiary—each with a different underlying cause and physiological mechanism. Understanding these distinctions is fundamental to accurate diagnosis and treatment.

Primary Hyperparathyroidism

Primary hyperparathyroidism (PHPT) is the focus of our discussion. In this condition, the problem originates within the parathyroid glands themselves. One or more of the four parathyroid glands develops a benign tumor, called an adenoma, or, less commonly, becomes enlarged, a condition known as hyperplasia. This abnormal gland tissue becomes autonomous and produces an excessive amount of parathyroid hormone (PTH), irrespective of the body’s actual calcium levels.
The normal feedback loop is broken. In a healthy individual, high blood calcium would signal the parathyroid glands to stop producing PTH. In PHPT, the adenoma continues to churn out PTH, leading to a classic biochemical signature:

High Serum Calcium
High or Inappropriately Normal PTH

Secondary Hyperparathyroidism

In secondary hyperparathyroidism, the parathyroid glands are not the source of the problem. They are actually functioning correctly, but they are responding to another underlying disease state that is causing low calcium levels (hypocalcemia). The glands become enlarged and overproduce PTH as a compensatory mechanism to try and raise the blood calcium back to normal.
The most common causes of secondary hyperparathyroidism are:

Chronic Kidney Disease (CKD): This is the most prevalent cause. As kidney function declines, the kidneys are unable to excrete phosphate effectively and lose the ability to activate vitamin D. The combination of low calcium and high phosphate creates a powerful stimulus for the parathyroid glands to produce massive amounts of PTH.
Vitamin D Deficiency: A severe and prolonged deficiency of vitamin D leads to poor calcium absorption from the diet, triggering the parathyroid glands to ramp up PTH production.

The biochemical profile of secondary hyperparathyroidism is typically: Low or Normal Serum Calcium and High PTH.

Tertiary Hyperparathyroidism

Tertiary hyperparathyroidism is a complication that arises from long-standing, severe secondary hyperparathyroidism, most often in patients with end-stage renal disease. After years of constant stimulation, the parathyroid glands become so enlarged and hyperplastic that they begin to function autonomously, similar to a primary adenoma. They continue to secrete massive amounts of PTH even if the original problem is corrected (e.g., after a kidney transplant), leading to significant hypercalcemia.
The biochemical profile of tertiary hyperparathyroidism is: High Serum Calcium and Very High PTH.

Differentiating the Causes of Elevated Calcium and PTH

When we have confirmed that a patient has both elevated calcium and elevated parathyroid hormone (PTH), we have significantly narrowed our differential diagnosis. The primary culprit we focus on is primary hyperparathyroidism. However, before finalizing this diagnosis, it’s crucial to rule out other factors that can create a similar lab profile.

The Role of Medications

Thiazide Diuretics: Medications like hydrochlorothiazide (HCTZ) increase the reabsorption of calcium from the urine back into the blood. This can lead to elevated serum calcium levels and a slightly elevated PTH. In such cases, if clinically appropriate, I work with the patient’s primary care provider to temporarily hold the diuretic and recheck labs.
Lithium: This medication, used for bipolar disorder, increases the “set point” for calcium, desensitizing the parathyroid glands to calcium. The result is both hypercalcemia and elevated PTH. Managing this requires close collaboration with the patient’s mental health provider.

Rare Genetic Conditions

Familial Hypocalciuric Hypercalcemia (FHH): This is a benign autosomal dominant genetic disorder that affects the calcium-sensing receptor (CaSR). This leads to lifelong mild hypercalcemia, inappropriately normal or mildly elevated PTH, and low urinary calcium excretion (hypocalciuria). The key diagnostic test is a 24-hour urine calcium collection. A very low result (calcium-to-creatinine clearance ratio < 0.01) points to FHH, a condition that does not benefit from parathyroid surgery.
Familial Hyperparathyroidism and Multiple Endocrine Neoplasia (MEN) Syndromes: If I encounter a patient with primary hyperparathyroidism who is under the age of 30, a red flag is immediately raised. This early onset suggests a possible genetic predisposition, such as Multiple Endocrine Neoplasia (MEN) type 1 (Parathyroid, Pituitary, Pancreatic tumors) or type 2A (Medullary thyroid cancer, Pheochromocytoma, Parathyroid hyperplasia). These patients often have multi-gland involvement and require genetic testing and lifelong screening.

A Visual Guide to Interpreting Lab Results

To simplify the process of differentiating these conditions, I find visual aids to be incredibly helpful. The following breakdown provides a clear framework for interpreting the key lab values: calcium and PTH.

Serum Calcium	Parathyroid Hormone (PTH)	Probable Diagnosis
High	High or Normal	Primary Hyperparathyroidism or Tertiary Hyperparathyroidism
Normal	High	Normocalcemic Primary Hyperparathyroidism or Secondary Hyperparathyroidism
Low	High	Secondary Hyperparathyroidism
High	Low	Hypercalcemia of Malignancy, Vitamin D Toxicity, etc.
Low	Low	Hypoparathyroidism

A Closer Look at Normocalcemic Primary Hyperparathyroidism

One of the more challenging diagnostic puzzles is Normocalcemic Primary Hyperparathyroidism (NPHPT). This is a distinct subgroup of patients who have persistently elevated PTH levels but consistently normal total and ionized calcium levels. Diagnosing NPHPT requires a careful and systematic process of exclusion. We must be certain that we are not dealing with a case of secondary hyperparathyroidism.
The key criteria for diagnosing NPHPT are:

Normal Calcium Levels: Confirmed over several tests.
Elevated Parathyroid Hormone (PTH): Confirmed on at least two separate occasions.
Exclusion of All Secondary Causes: This is the most critical step and involves a comprehensive workup to rule out Vitamin D Deficiency (level must be >30 ng/mL), Renal Insufficiency (GFR must be >60 mL/min), and the influence of medications or malabsorption issues.

Only after this exhaustive process can we confidently diagnose NPHPT. It is considered an early form of primary hyperparathyroidism, and studies have shown that a significant percentage of these patients will eventually progress to develop hypercalcemia over time.

The Essential Diagnostic Workup for Primary Hyperparathyroidism

Once we suspect primary hyperparathyroidism, a structured and comprehensive workup is necessary to confirm the diagnosis, assess its severity, and determine the best course of treatment.

Crucial Laboratory Tests

Comprehensive Metabolic Panel (CMP): Provides Serum Calcium, Albumin (to calculate corrected calcium), and Renal Function (Creatinine/eGFR).
Intact Parathyroid Hormone (PTH): The cornerstone test. An elevated or “inappropriately normal” PTH level in the presence of high calcium confirms the diagnosis.
25-Hydroxy Vitamin D: Essential to rule out vitamin D deficiency as a cause of secondary hyperparathyroidism.
Serum Phosphorus: Often low or low-normal in PHPT because PTH causes the kidneys to waste phosphate.
24-Hour Urine Collection for Calcium and Creatinine: Vital to assess kidney stone risk and to differentiate PHPT from Familial Hypocalciuric Hypercalcemia (FHH).

Essential Imaging Tests

These imaging studies are not used to diagnose the condition, but to stage its severity and help determine if a patient meets criteria for surgery.

DEXA Scan (Dual-Energy X-ray Absorptiometry): A bone mineral density scan is crucial to evaluate for osteoporosis. We must specifically request a measurement of the distal one-third radius (the forearm), a site rich in cortical bone, which is preferentially affected by high PTH levels.
Renal Imaging (Ultrasound, CT, or X-ray): We need to look for evidence of kidney stones (nephrolithiasis) or calcium deposits in the kidney tissue (nephrocalcinosis).
Pre-operative Localization Imaging (Neck Ultrasound and Sestamibi Scan): These tests are ordered only after the decision for surgery is made. Their sole purpose is to help the surgeon locate the abnormal parathyroid gland(s) before the operation. 4D-CT and MRI are other options for challenging cases.

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”- Video

Global Differences in PHPT Presentation: The Tale of Two Cities

In a comparative study that I refer to as “The Tale of Two Cities,” investigators evaluated PHPT presentations among cohorts in the United States and Beijing, China. The findings reveal striking contrasts:
United States:

Typical presentation: asymptomatic hypercalcemia, often in postmenopausal women.
Average vitamin D: roughly 21 ng/mL.
Kidney stone incidence: 15–20%.
Skeletal involvement: primarily detected by bone densitometry.

Beijing, China:

Average age: ~37 years, significantly younger.
Average calcium and PTH levels are much higher.
Average vitamin D: ~8.8 ng/mL, profoundly low.
Radiologic osteitis fibrosa cystica is evident in ~60% of patients.
Pathologic fractures are common (~35%).

Interpretation: Vitamin D deficiency appears as a major amplifying factor, intensifying skeletal turnover and disease severity. This highlights the importance of screening for and treating vitamin D deficiency in all PHPT patients.

Determining the Need for Surgery: Key Indications

The only definitive cure for primary hyperparathyroidism is a parathyroidectomy. However, not every patient needs surgery. International consensus guidelines have established specific criteria to identify who is most likely to benefit. A patient should be offered surgery if they meet any one of the following criteria:

Indication for Surgery	Explanation
Age < 50 years	Younger patients have a longer lifetime to suffer the consequences of untreated hypercalcemia, such as bone loss and kidney damage.
Serum Calcium Level	A serum calcium level that is more than 1.0 mg/dL above the upper limit of the laboratory’s normal range.
Bone Mineral Density	A T-score of -2.5 or lower at any of the three measured sites (lumbar spine, femoral neck, or distal 1/3 radius), which indicates osteoporosis, or a history of a fragility fracture.
Kidney Involvement	Reduced Kidney Function (eGFR of less than 60 mL/min) OR High Urine Calcium & Stone Risk (24-hour urinary calcium excretion > 400 mg/day or presence of kidney stones on imaging).

Observation vs. Surgery: Personalized Pathways and Quality of Life

For asymptomatic patients who do not meet surgical criteria, watchful waiting can be a valid approach. In fact, a significant study I often share with patients examined whether parathyroidectomy improves quality of life compared with observation. Over ten years of prospective, randomized follow-up, the study found that while surgery cured the biochemical abnormalities, it did not necessarily improve overall quality of life compared to the observation group. This empowers patients to consider non-surgical observation and teaches clinicians to avoid overpromising global life-quality improvements from surgery, while still acknowledging the clear benefits for bone and kidney health.
This is why we create a personalized plan that includes:

Regular labs: calcium, PTH, creatinine/eGFR, vitamin D.
Periodic DEXA scans for bone health.
Renal ultrasounds if stone risk is present.
Lifestyle strategies: hydration, mobility, nutrition.

The Surgical Solution and the Importance of an Experienced Surgeon

When a patient meets the criteria for surgery, the next step is a referral to a high-volume, experienced parathyroid surgeon. This cannot be overstated. These specialist surgeons have significantly higher success rates and lower complication rates.

The Surgical Procedure

The procedure, a parathyroidectomy, is highly effective, achieving a biochemical cure in approximately 98% of patients. In about 80-90% of cases, PHPT is caused by a single benign parathyroid adenoma, which can be removed through a minimally invasive approach. To confirm success, surgeons use intraoperative PTH monitoring. Since PTH has a short half-life (~3–5 minutes), a >50% drop from the baseline level after the gland is removed confirms that the source of the excess hormone has been eliminated.

The Benefits of Surgery

Normalization of Lab Values: Serum calcium, PTH, and urinary calcium levels return to normal.
Improvement in Bone Density: Bone density begins to improve, reducing long-term fracture risk.
Decreased Risk of Kidney Stones: The risk of forming future kidney stones is significantly reduced.
Potential Improvement in Neurocognitive Symptoms: Many patients report a significant improvement in fatigue, “brain fog,” and mood.

Medical Management: When Surgery Isn’t the Answer

For patients who are not surgical candidates or choose a non-surgical path, we transition to a strategy of medical management and active surveillance.

Pharmacological Intervention: Cinacalcet and Bisphosphonates

Cinacalcet (Sensipar): For patients with significantly high calcium levels, this medication can be a game-changer. Cinacalcet is a calcimimetic, meaning it “mimics” the action of calcium. It binds to the calcium-sensing receptors on the parathyroid glands, tricking them into thinking calcium is high and causing them to decrease PTH production. This lowers both PTH and serum calcium levels. The typical starting dose is 30 mg twice a day, which can be titrated upwards based on the patient’s response.
Antiresorptives (Bisphosphonates or Denosumab): If a patient has co-existing osteoporosis, they should be treated for it. Medications like bisphosphonates (e.g., alendronate, zoledronic acid) are effective at increasing bone density by inhibiting the osteoclasts that break down bone.

Essential Patient Education

Hydration is Non-Negotiable: Dehydration concentrates blood calcium and can cause a dangerous spike. Patients must be vigilant about drinking plenty of fluids.
Stay Active: Regular, weight-bearing physical activity is essential for maintaining bone health.
Be Smart About Calcium Intake: Patients should stop taking calcium supplements. However, they should not go on a low-calcium diet, as this can backfire and further stimulate PTH production. A moderate intake of 1,000 to 1,200 mg per day from dietary sources is a reasonable goal.

The Role of Integrative Chiropractic Care in Hyperparathyroidism

While medical management focuses on controlling calcium and PTH, an integrative approach that includes chiropractic care can be profoundly beneficial for addressing the widespread musculoskeletal symptoms of the disease.
Key components of our integrative chiropractic care include:

Biomechanical Assessment and Gentle Manual Therapy: We evaluate and treat spinal alignment, pelvic tilt, and compensatory patterns resulting from bone density changes or chronic pain. We use soft-tissue work and low-force adjustments (e.g., instrument-assisted techniques) to reduce pain and improve range of motion without stressing osteopenic bones.
Fracture Risk Mitigation and Safety: We avoid high-velocity thrusts in patients with severe bone loss. Safety in manual therapy is paramount; we emphasize soft tissue release, joint mobilization, and motor control training over aggressive maneuvers.
Neuromuscular Stabilization and Posture Retraining: We target deep stabilizing muscles to protect the spine and improve functional movement. We also provide ergonomic coaching and encourage movement variety to prevent immobilization-related hypercalcemia.
Balance and Fall Prevention: Proprioceptive and vestibular training are crucial to reduce fracture risk, especially in older adults.
Rehabilitation Integration: We design progressive resistance exercise programs tailored to bone health status. Load management through mechanotransduction is a powerful signal for improving bone strength.

My clinical observations show that coordinated manual therapy and targeted exercise significantly reduce pain and improve daily function for PHPT patients. Each intervention is selected with bone health in mind, protecting fragile structures while restoring resilience.

Functional Medicine Integration: Addressing Root Causes and Systems Biology

Our functional medicine approach complements medical and chiropractic care by addressing the whole person.

Nutrition Strategy: We focus on adequate protein for the bone matrix, Vitamin K2 to help guide calcium to bone, magnesium sufficiency for PTH regulation, and omega-3 fatty acids to modulate inflammation.
Gut Health: We address dysbiosis or malabsorption issues that can alter vitamin and mineral absorption.
Sleep and Circadian Rhythm: We provide strategies to improve sleep architecture, as poor sleep impacts endocrine balance.
Stress Physiology: We use mind-body practices like meditation and diaphragmatic breathing to reduce the negative impact of chronic stress on bone remodeling.
Environmental and Medication Review: We identify and mitigate contributors to hypercalcemia, such as certain medications or excessive supplement intake.

Personal Injury Care: Calcium and PTH in the Context of Trauma

Injury settings introduce unique dynamics. Immobilization increases bone resorption, raising calcium and potentially dysregulating PTH. Our protocol for personal injury patients involves early mobilization plans, hydration strategies, regular lab monitoring during recovery, and nutritional support to counter catabolic stress. Dr. Cardenas’s internal medicine oversight ensures safe integration of all care, while my team provides hands-on rehabilitation to restore function without overloading weakened bone.

Case Narratives: Translating Physiology into Practice

I believe case narratives bring science to life. Here are a few that illustrate our integrative approach.

Case 1: An 85-Year-Old Female with Severe Hypercalcemia

An 85-year-old female with dementia presented to the ER with weakness and confusion, with a calcium level of 15.8 mg/dL. After ruling out malignancy, her family elected for non-surgical management. Under Dr. Cardenas’s direction, she was managed with a maximum dose of cinacalcet (90 mg twice daily), intermittent infusions of zoledronic acid, and aggressive hydration. My team focused on caregiver education, fall prevention, and gentle mobility to maintain function and safety. This case highlights how rigorous medical management can stabilize frail, high-risk patients.

Case 2: A 68-Year-Old Male with Cardiovascular Disease and PHPT

This patient was referred by his cardiologist. He met surgical criteria and underwent a successful parathyroidectomy. Post-operatively, he reported immediate improvement in energy. However, his PTH remained elevated. We identified ongoing vitamin D insufficiency as a likely contributor. Under Dr. Cardenas’s oversight, we initiated vitamin D repletion. From the chiropractic side, we supported his return to activity with a graded plan focusing on thoracic mobility and respiratory mechanics to support his cardiovascular endurance.

Case 3: A 57-Year-Old Male Pilot with PHPT and Chronic Foot Pain

This patient had elevated calcium, a non-obstructing kidney stone, and long-standing, significant bilateral foot pain. After a successful parathyroidectomy, his calcium and PTH normalized, and he reported a dramatic improvement in his chronic foot pain. This illustrates how chronic skeletal pain can be amplified by hypercalcemia. Post-operatively, I managed the mechanics of his foot and ankle, focusing on gait and strengthening, which allowed him to recover fully. Musculoskeletal pain often reflects systems biology—aligning surgical cure with biomechanical rehabilitation yields substantial functional gains.
My clinical observations and professional experience can be further explored at:

Frequently Asked Questions: Patient-Friendly Explanations

Why do I feel fine if my calcium is high? Mild elevations can be “silent.” Over time, subtle symptoms emerge; early management prevents complications.
Is surgery always necessary? Not always. Indications depend on symptoms, calcium level, bone and kidney status, and patient preference.
Should I take vitamin D? Many benefit from careful repletion, but dosing must be personalized and monitored to avoid worsening hypercalcemia.
What does chiropractic add? Pain relief, posture improvement, safe movement, fall prevention, and rehabilitation tailored to bone health, integrated with medical oversight.
Will exercise help? Yes—properly dosed exercise strengthens bone and stabilizes musculoskeletal function. We design safe, progressive plans.

Closing Reflections: From Calcium Chaos to Clarity

Hyperparathyroidism spans an intricate network of bones, kidneys, nerves, and hormones. The promise of modern care—rooted in leading research and delivered through multidisciplinary integration—is that we can turn calcium chaos into clarity. With internal medicine leadership from Dr. Maria Guadalupe Cardenas and integrative chiropractic and functional medicine care at Injury Medical Clinic PA, we help patients regain control, relieve symptoms, protect their bones and kidneys, and thrive.

References

SEO Tags: hyperparathyroidism, primary hyperparathyroidism, parathyroid hormone, PTH, hypercalcemia, calcium, ionized calcium, vitamin D, cholecalciferol, ergocalciferol, calcitriol, nephrolithiasis, osteoporosis, parathyroidectomy, sestamibi, 4D-CT, cinacalcet, bisphosphonates, denosumab, functional medicine, chiropractic care, integrative medicine, internal medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso TX, osteitis fibrosa cystica, multiple endocrine neoplasia, MEN syndrome, familial hypocalciuric hypercalcemia, FHH, DEXA scan, quality of life, observation vs surgery, rehabilitation

July 2, 2026

Cardiometabolic Research Advances Using GLP-1 Receptor Therapy

Find out about GLP-1 receptor therapy on cardiometabolic health and its revolutionary role in modern medicine and patient care.

Abstract

Hello, I’m Dr. Alex Jimenez, and I am honored to share transformative insights into managing cardiovascular and metabolic conditions, such as type 2 diabetes. This educational post explores a significant shift in our medical understanding, moving from a purely glucose-centric model to a comprehensive, risk-reduction strategy. Here, we will journey through the latest findings from leading researchers, backed by robust, evidence-based studies, to understand this new paradigm. We’ll delve into the mechanisms of two groundbreaking classes of medications—SGLT2 inhibitors and GLP-1 receptor agonists—and their profound benefits for cardiovascular and renal health, often independent of their glucose-lowering effects. We will also discuss how our multidisciplinary team at Injury Medical Clinic PA, including the invaluable medical direction of Dr. Maria Guadalupe Cardenas, MD, integrates these advancements with integrative chiropractic care, functional medicine, and rehabilitation to provide a truly holistic treatment plan for our patients in El Paso, Texas. This post aims to illuminate the interconnectedness of cardiac, metabolic, and kidney health and present a collaborative path forward for optimal patient outcomes.

Our Collaborative and Integrative Practice at Injury Medical Clinic PA

Before we delve into the clinical science, I want to take a moment to explain our unique approach to patient care here in El Paso, Texas. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, we have built a truly multidisciplinary practice. I am Dr. Alex Jimenez, and my credentials include DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST. My passion lies in functional medicine and chiropractic care, focusing on the body’s innate ability to heal and the musculoskeletal system’s foundational role in overall health.
A cornerstone of this model is my collaboration with Dr. Maria Guadalupe Cardenas, MD. With over 40 years of experience as a board-certified internist, Dr. Cardenas serves as our Medical Director and Collaborative Physician (NPI #1164426749, Texas MD License #J2933). Her extensive expertise in internal medicine provides essential medical oversight and direction, allowing us to seamlessly merge advanced medical protocols with chiropractic, functional medicine, rehabilitation, and personal injury care.
Our model is built on the synergy between different disciplines:

Medical Oversight (Dr. Cardenas): Provides diagnoses, prescribes medications like the advanced therapies we will discuss today, and oversees the overall medical treatment plan, ensuring patient safety and efficacy.
Chiropractic and Functional Medicine (Dr. Jimenez): I focus on identifying and addressing the root causes of dysfunction. Through chiropractic adjustments, we restore proper nerve function and biomechanics. With functional medicine, we analyze a patient’s genetics, lifestyle, and environment to correct underlying imbalances in metabolism, inflammation, and gut health.
Integrated Services: Together, we manage personal injury cases, rehabilitation, nutritional counseling, and chronic disease management. This team-based approach ensures that a patient with diabetes, for example, not only receives the latest medications but also benefits from dietary overhauls, targeted supplementation, and structural care to improve insulin sensitivity and reduce systemic inflammation. This is the essence of integrative medicine—uniting the best of multiple worlds for superior patient outcomes.

The Critical Link Between Diabetes and Cardiovascular Disease

For a long time, the primary focus in managing type 2 diabetes was on lowering blood glucose. While important, this approach was incomplete. We now have an overwhelming body of evidence showing that people with diabetes face a significantly elevated risk for Atherosclerotic Cardiovascular Disease (ASCVD), which includes coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death for individuals with diabetes.

Consider this startling fact: over 70% of individuals with diabetes over the age of 65 will likely succumb to heart disease or a stroke.
Following a heart attack (myocardial infarction or MI), people with diabetes have a much higher mortality risk and a poorer long-term prognosis.
These grim outcomes persist even when blood sugar levels are well-controlled, and they affect individuals with both type 1 and type 2 diabetes.

This reality has forced a paradigm shift in how we manage these interconnected conditions. The focus has expanded from aggressive glucose reduction to a holistic strategy to reduce overall cardiovascular and renal risk. This involves managing not just blood sugar, but also blood pressure, cholesterol levels, weight, physical activity, and smoking cessation. For the first time in my career, all the major guideline-issuing bodies—including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease: Improving Global Outcomes (KDIGO)—are in complete agreement on this new, integrated approach to care. This consensus marks a monumental step forward, allowing us to view and treat our patients through a unified, comprehensive lens.

Rethinking Treatment Algorithms: A Risk-Based Approach

This new paradigm is reflected in the latest treatment algorithms from the American Diabetes Association. The guidelines now emphasize a risk-stratified approach. For any patient with type 2 diabetes who has established ASCVD, heart failure, chronic kidney disease (CKD), or is at high risk for developing these conditions, the recommendation is to concurrently address all risk factors and prioritize specific classes of medications.
The algorithm directs us to move beyond traditional first-line agents like metformin alone and immediately consider two powerful classes of drugs:

SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors
GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists

These medications are now recommended as foundational therapies for high-risk patients precisely because they have demonstrated proven cardiovascular (CV) benefits in large-scale clinical trials. The choice between them, or the decision to use them in combination, depends on patient-specific factors, comorbidities, and preferences. This marks a significant departure from simply trying to lower the A1C; it’s about proactively protecting the heart and kidneys.

The History and Evolution of Diabetes Medication Trials

How did we arrive at this pivotal moment? The story begins around 2008, when the U.S. Food and Drug Administration (FDA) issued mandatory guidance for all new antidiabetic medications. The FDA required pharmaceutical companies to conduct long-term Cardiovascular Outcomes Trials (CVOTs). The primary goal was to ensure that these new drugs did not increase the risk of Major Adverse Cardiovascular Events (MACE)—a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death.
This mandate was a direct response to past experiences where certain drugs, such as rosiglitazone (Avandia) and others like Vioxx, were later found to cause cardiovascular harm. Earlier studies were often too short, underpowered, or poorly designed to detect these risks. The FDA’s new requirement forced the industry to conduct large, well-designed, placebo-controlled trials that were robust enough to demonstrate safety or non-inferiority.
What happened next was truly surprising. As the results of these CVOTs began to be published, starting with the EMPA-REG OUTCOME trial for empagliflozin (Jardiance) in 2015, researchers discovered something extraordinary. These new drugs weren’t just safe—some of them were actively protective.

Empagliflozin (Jardiance), an SGLT2 inhibitor, was the first to show a significant reduction in MACE, CV death, and hospitalization for heart failure.
Liraglutide (Victoza), a GLP-1 receptor agonist, followed in 2016 with the LEADER trial, also demonstrating significant cardiovascular benefits.

These unexpected findings of superiority, not just safety, were game-changers. They provided the evidence needed to completely overhaul the clinical guidelines and place these drug classes at the forefront of managing patients with cardiovascular, metabolic, and renal disease.

A Deeper Dive into SGLT2 Inhibitors

Let’s explore the SGLT2 inhibitor class more closely. These medications work by blocking glucose reabsorption in the kidney, causing excess sugar to be excreted in the urine. While this helps lower blood glucose, their profound cardiovascular and renal benefits appear to stem from multiple other mechanisms.

Landmark Cardiovascular Outcomes Trials for SGLT2 Inhibitors

Several major CVOTs have established the benefits of this class:

EMPA-REG OUTCOME (empagliflozin/Jardiance): This trial was a watershed moment. It showed a highly statistically significant reduction in MACE, CV death, and hospitalization for heart failure.
CANVAS Program (canagliflozin/Invokana): Demonstrated significant reductions in MACE and hospitalization for heart failure.
DECLARE-TIMI 58 (dapagliflozin/Farxiga): While it didn’t show a significant reduction in MACE, it showed a substantial and statistically significant reduction in the risk of hospitalization for heart failure.
VERTIS-CV (ertugliflozin/Steglatro): Also showed a significant reduction in hospitalization for heart failure risk (a 30% relative risk reduction).

The consistent and powerful effect on reducing hospitalizations for heart failure across the class is particularly noteworthy and has led to their widespread adoption in cardiology.

The Multifaceted Mechanisms of SGLT2 Inhibitors

What makes these drugs so effective? The benefits go far beyond simple glucose lowering. Some of the proposed mechanisms that contribute to their cardioprotective and renoprotective effects:

Hemodynamic Effects: SGLT2 inhibitors have a mild diuretic effect, which helps reduce blood pressure by about 3-5 mmHg systolic. This is achieved through natriuresis, or the excretion of sodium and water, which reduces fluid volume and preload on the heart.
Reduced Glomerular Pressure: In the kidneys, these drugs reduce pressure within the glomerulus (the kidney’s filtering unit). This is a key theorized mechanism for their nephroprotective (kidney-protecting) effects, slowing the progression of diabetic kidney disease.
Metabolic Shifts: SGLT2 inhibitors promote a slight shift towards ketosis. The heart is a unique metabolic organ that can efficiently use ketones as a fuel source. This “super fuel” improves myocardial efficiency and function, especially in a stressed or failing heart.
Systemic Benefits: They also contribute to a modest weight loss (around 5-7 pounds), reduce inflammation, decrease oxidative stress, and may improve endothelial function and stabilize atherosclerotic plaques.
Improved Myocardial Energetics: By reducing the workload on the heart (via lower blood pressure and volume) and providing a more efficient fuel source (ketones), these drugs improve the overall energy balance and function of the heart muscle.

SGLT2 Inhibitors in Heart Failure and Kidney Disease

The benefits of SGLT2 inhibitors have been so profound that their use has expanded to patients without diabetes.

Heart Failure Trials

DAPA-HF and EMPEROR-Reduced: These trials studied dapagliflozin and empagliflozin, respectively, in patients with heart failure with reduced ejection fraction (HFrEF). Both showed a remarkable 25-26% relative risk reduction in the composite outcome of cardiovascular death or hospitalization for heart failure, regardless of whether the patients had diabetes.
EMPEROR-Preserved: This was the first trial to show a meaningful benefit in patients with heart failure with preserved ejection fraction (HFpEF), a very common and difficult-to-treat type of heart failure, particularly in older adults, women, and those with obesity. Empagliflozin reduced the primary composite endpoint by 21%.

Kidney Disease Trials

The evidence for kidney protection is just as compelling:

DAPA-CKD (dapagliflozin): This trial was stopped early due to overwhelming efficacy. It showed a 39% reduction in the risk of progression of kidney disease.
EMPA-KIDNEY (empagliflozin): Also demonstrated a significant 28% reduction in the risk of kidney disease progression or cardiovascular death.
CREDENCE (canagliflozin): Showcased a 30% reduction in the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and kidney disease.

These trials have firmly established SGLT2 inhibitors as a cornerstone therapy for chronic kidney disease, even in patients without diabetes.

Understanding the Incretin Effect: TheBody’ss Natural Glucose Response System

For years, the management of type 2 diabetes centered on a few key strategies. However, a fascinating discovery completely shifted our understanding and opened the door to a new class of powerful therapies. Researchers observed a peculiar phenomenon: when people consumed glucose orally (by drinking it), their bodies produced a much more robust insulin response to lower blood sugar than when the same amount of glucose was administered intravenously (IV). This observation led them to a logical conclusion: there must be something happening in the gut when food is ingested that signals the pancreas to ramp up insulin production.
This phenomenon was termed the “incretin effect.” The “somethings” responsible were identified as gut hormones called incretins, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

The Process: When you eat, food travels to your stomach and intestines. Specialized cells in your gut (L-cells) detect the presence of nutrients and release GLP-1 and GIP into your bloodstream.
The Signal: These hormones then travel to the pancreas, where they act as messengers. They bind to receptors on pancreatic beta cells, stimulating the cells to release insulin.
The Result: This insulin release helps your body’s cells take up glucose, effectively lowering your blood sugar levels after a meal.

Crucially, this entire process is glucose-dependent. This means the incretins only stimulate insulin release when blood sugar levels are high, as they are after a meal. This built-in safety mechanism significantly reduces the risk of hypoglycemia (dangerously low blood sugar) when these pathways are targeted with medication, especially compared to older diabetes drugs.

The Blunted Incretin Effect in Type 2 Diabetes

One of the key physiological defects we see in patients with type 2 diabetes is a blunted or even absent incretin effect. Their bodies produce insufficient amounts of native GLP-1 in response to food. This deficiency contributes significantly to the hallmarks of the disease:

Poor Post-Meal Glucose Control: Without a strong incretin signal, the pancreas doesn’t release sufficient insulin after eating, resulting in prolonged periods of high blood sugar.
Dysregulated Appetite: Native GLP-1 also plays a critical role in promoting satiety, or the feeling of fullness. Low levels of this hormone can lead to a state of poor satiety, contributing to overeating and the obesity that is so often a comorbid condition with type 2 diabetes.
Excess Glucagon Secretion: GLP-1 normally helps suppress the release of another hormone called glucagon. Glucagon tells the liver to produce and release more sugar into the bloodstream (gluconeogenesis). In type 2 diabetes, this suppression is impaired, so the liver continues to release glucose even when blood glucose is already high.

Understanding this hormonal defect was the key that unlocked the development of GLP-1 receptor agonists—medications designed to mimic the action of our natural GLP-1 and restore these vital functions.

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

How GLP-1 Receptor Agonists Revolutionize Treatment

GLP-1 receptor agonists are a class of medications that bind to and activate GLP-1 receptors throughout the body, just as our native GLP-1 would, but they are engineered to last much longer. Their multifaceted mechanism of action addresses several core issues in type 2 diabetes and obesity simultaneously.

Stimulates Insulin Secretion: By activating pancreatic receptors, they prompt a glucose-dependent release of insulin, directly lowering blood sugar.
Inhibits Glucagon Secretion: They effectively tell the liver to stop producing excess sugar, which is a major contributor to high fasting and post-meal glucose levels.
Slows Gastric Emptying: This is a key mechanism for both glucose control and weight loss. By slowing down the rate at which food leaves the stomach, they prevent rapid spikes in blood sugar after meals. This delay also contributes to a prolonged feeling of fullness, which naturally leads to a decrease in overall food intake. This effect is often responsible for the common initial side effects like nausea, but it is also a primary driver of the medication’s success.
Increases Satiety: GLP-1 receptor agonists act directly on appetite centers in the brain, enhancing the feeling of fullness and reducing food cravings. This neurobiological effect is fundamental to the significant weight loss seen with these therapies.

Collectively, these actions lead to profound improvements in A1c, blood glucose, and body weight, tackling the metabolic dysfunction of type 2 diabetes at its source.

The Challenge of Over-Basalization: A Case Study

To truly understand the paradigm shift in diabetes care,let’ss consider a typical patient I might see in our clinic, whom we’ll call Tony. He represents a common challenge where adding a GLP-1 agonist is the superior strategy.

Patient Profile: Tony
Age: 62 years
Diagnosis: Type 2 Diabetes (11 years), Hyperlipidemia, Hypertension
Recent A1c: 8.2% (well above the target of <7.0%)
Kidney Health: Proteinuria (protein in the urine), an early sign of kidney damage.
Current Medications:
- Degludec (basal insulin): 65 units daily
- Metformin: 1000 mg twice daily
- An SGLT2 inhibitor daily
- A statin for cholesterol
An ARB for blood pressure
Physical Stats: Weight 220 lbs, Height 5’9 ” “, BMI 32.5 (classifies as obese)
Blood Sugar Patterns:
- Fasting Glucose (morning): 15050 mg/dL
- Postprandial Glucose (after meals/bedtime): 160-200 mg/dL

Tony’s case highlights a critical issue we call over-basalization. We’ve pushed his basal (long-acting) insulin dose to a high level, yet his A1c and post-meal sugars remain dangerously elevated. Research in pharmacokinetics reveals that once you exceed a certain dose of basal insulin, typically around 0.5 units per kilogram of body weight per day, you get diminishing returns. For Tony, who weighs 100 kg (220 lbs), this threshold is about 50 units. He is already on 65 units, pushing him past the point of modest glycemic effect and into the territory of significant side effects, primarily weight gain and a higher risk of hypoglycemia.
For a patient like Tony, the conventional next step might have been to add prandial (mealtime) insulin. While this can control post-meal spikes, it comes with a heavy price: a near-certainty of further weight gain and a significantly increased risk of hypoglycemia. Given his BMI of 32.5, adding more weight would only worsen his insulin resistance, creating a vicious cycle.
This is where the 2024 guidelines from the American Diabetes Association (ADA) strongly recommend adding a GLP-1 receptor agonist. It addresses multiple problems at once, moving beyond simple glucose lowering, weight loss, and cardiovascular protection, which are crucial for a high-risk patient like Tony.

Beyond Blood Sugar: The Cardiovascular and Renal Benefits of GLP-1s

Perhaps the most exciting development in the story of GLP-1 agonists is the overwhelming evidence of their protective effects on the heart and kidneys. Several landmark trials have established these powerful benefits:

The LEADER Trial (Liraglutide): This trial studied patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction in the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, and non-fatal stroke.
The SUSTAIN-6 and PIONEER 6 Trials (Semaglutide): Both the injectable (SUSTAIN-6) and oral (PIONEER 6) forms of semaglutide were studied in patients with high cardiovascular risk. Both trials demonstrated a robust reduction in MACE, confirming the class effect.
The REWIND Trial (Dulaglutide): What made this trial unique was its focus on a broader population, including many patients who had risk factors for cardiovascular disease but had not yet had an event. It demonstrated that dulaglutide can be used for primary prevention, reducing the risk of a first cardiovascular event.
Tirzepatide (Mounjaro®, Zepbound™): This is a newer, highly potent dual GIP/GLP-1 receptor agonist. While its final CVOTs are still pending as of June 15, 2026, preliminary data suggest powerful cardiovascular benefits are likely.

More recently, the FLOW trial for semaglutide was stopped early because of overwhelmingly positive results showing a significant reduction in the risk of kidney disease progression (nephropathy). These findings are game-changers, solidifying the role of GLP-1 agonists as essential therapies for patients with or at high risk for heart and kidney disease.

Navigating Side Effects and Safety Considerations of GLP-1 Agonists

As with any potent medication, GLP-1 agonists are not without side effects. As clinicians, our job is to help patients navigate these challenges.

Gastrointestinal (GI) Issues: Nausea, vomiting, and diarrhea are common and caused by delayed gastric emptying. My clinical advice is always to “start low and go slow,” beginning with the lowest dose and titrating upwards gradually.
Dehydration and Acute Kidney Injury (AKI): Patients on these medications must drink plenty of water to prevent dehydration due to GI side effects.
Gallbladder Disease: Rapid weight loss, regardless of the method, is associated with an increased risk of gallstone formation.
Pancreatitis: Recent large-scale studies as of early 2025 have been reassuring, finding no statistically significant increase in the risk of pancreatitis and even suggesting a potential long-term risk reduction by improving metabolic health.
Thyroid C-Cell Tumors: These medications carry a black box warning due to an increased risk of thyroid C-cell tumors in rodents. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Muscle and Bone Loss: This is a feature of significant weight loss in general, not something specific to these drugs. This is where our integrative care becomes critical.

An Integrative Chiropractic Perspective on Metabolic Health

As a Doctor of Chiropractic with advanced training in functional medicine, I view the body as an integrated system. When I see a patient, I don’t just see a person with diabetes and heart disease. I see a complex interplay of systemic inflammation, metabolic dysfunction, and biomechanical stress. This is where our unique approach at Injury Medical Clinic PA provides immense value. The side effects and physiological changes associated with modern diabetes therapies are whole-body issues we can address.
Here’s how integrative chiropractic care fits into this new paradigm:

Addressing Systemic Inflammation: Chronic inflammation is a root cause of both ASCVD and insulin resistance. Chiropractic adjustments have been shown to modulate the nervous system and can have a downstream effect on inflammatory pathways. By reducing spinal misalignments (subluxations), we can help normalize nerve function, which in turn influences the body’s inflammatory response.
Promoting Physical Activity and Combating Muscle Loss: Exercise is a critical component of managing diabetes. However, many patients are limited by musculoskeletal pain. As chiropractors, our primary role is to improve biomechanical function, reduce pain, and restore mobility. Furthermore, with the rapid weight loss induced by GLP-1s, there is a risk of sarcopenia (muscle loss). We implement targeted strength training and rehabilitation protocols to preserve and build lean muscle mass. By treating underlying musculoskeletal issues, we empower patients to engage in the physical activity necessary for their metabolic health.
Functional Medicine and Nutritional Counseling: My training as a Certified Functional Medicine Practitioner (CFMP) allows us to go deeper. We create personalized nutrition plans and recommend targeted supplementation to reduce inflammation, improve insulin sensitivity, and support cardiovascular health. To combat muscle loss, we ensure patients consume adequate protein to support muscle synthesis. This complements the work of medications by addressing the foundational lifestyle factors that drive disease.
Stress Management and Autonomic Balance: The autonomic nervous system plays a huge role in regulating blood pressure, heart rate, and metabolic function. Chronic stress leads to a state of sympathetic (“fight-or-flight”) dominance, which can worsen hypertension and insulin resistance. Chiropractic care, along with techniques like breathwork and meditation, helps promote a parasympathetic (“rest-and-digest”) state, supporting better cardiovascular and metabolic regulation.

In our clinic, a patient would receive a comprehensive plan. Under the medical direction of Dr. Cardenas, they might be started on an SGLT2 inhibitor or a GLP-1 agonist. Simultaneously, my team would work with them on a personalized plan including chiropractic adjustments to improve mobility, an anti-inflammatory diet, and a progressive exercise program they can perform without pain. This integrated approach addresses the disease from multiple angles, leading to far better and more sustainable outcomes. This is the future of chronic disease management—a holistic, patient-centered, and team-based model of care.

References

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, type 2 diabetes, chronic kidney disease, heart failure, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso, TX, ASCVD, risk reduction, metabolic health, incretin effect, over-basalization, tirzepatide, semaglutide, Mounjaro, Ozempic, diabetes management, A1c reduction, weight loss and diabetes, nephroprotection, cardioprotection, collaborative care, internal medicine, chiropractic, personal injury care, musculoskeletal health

June 26, 2026

Integrative Women’s Health Strategies for Balanced Hormones

Unlock the secrets of integrative hormones in women’s health and its impact on women’s lives at various stages.

Abstract

In this educational post, I will explore the intricate and often overlooked connections between women’s oral health, chronic disease, hormonal fluctuations, and the microbiome. We will journey through the latest evidence-based research, revealing how hormones like estrogen and progesterone directly impact the oral cavity, gut, and systemic inflammation from puberty through menopause. I review the bidirectional links between oral conditions and cardiometabolic, autoimmune, and pregnancy-related outcomes, and discuss how common medications can alter oral ecology. This post also delves into the oral-gut axis, explaining how oral health can influence your digestive system and vice versa. Furthermore, I will explain how our multidisciplinary team at Injury Medical Clinic PA provides a comprehensive, integrative approach. I will detail how the collaborative efforts of Dr. Maria Guadalupe Cardenas, MD, our esteemed Medical Director, and I integrate chiropractic care, functional medicine, rehabilitation, personal injury services, and internal medicine to address these complex health connections and support our patients on their path to optimal health.

Introduction: Women’s Oral Health Is Central to Whole-Person Care

I’m Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Over the last several years, I’ve deepened my focus on the connections between oral health and chronic disease—especially in women. Initially drawn by pregnancy-related implications and cardiovascular links, my diabetes work opened a broader window: the mouth is not separate from the body. It’s remarkable to learn that buccal epithelial cells (from the inside of your cheek) and vaginal epithelial cells share microscopic similarities, suggesting the same hormonal signals influence them. Oral health status reflects and shapes systemic inflammation, metabolic regulation, immune balance, and neuroendocrine signaling.

In this post, I share the latest findings from leading researchers and translate them into integrative clinical protocols. My goal is to give you a clear, step-by-step understanding of:

How hormones influence oral tissues across the female lifespan
Why the oral microbiome and gut microbiome co-direct systemic health
How common medications for chronic disease alter oral ecology and risk
What preventive strategies and integrative chiropractic care can add to management
How our multidisciplinary clinical model in El Paso integrates Internal Medicine, chiropractic, functional medicine, rehabilitation, and injury care to improve outcomes

Our Integrative Approach to Comprehensive Wellness in El Paso

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have built a practice on the principle of viewing the body as an integrated system. Our strength lies in our multidisciplinary collaboration, spearheaded by our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. With over 40 years of experience as a board-certified internist (NPI #1164426749, Texas MD License #J2933), Dr. Cardenas provides invaluable medical oversight and a deep well of clinical wisdom.

This unique structure, common in integrative or injury care clinics, allows us to offer a truly integrative model of care.

Dr. Cardenas oversees medical diagnostics, systemic risk stratification, labs, medication management, and inter-specialty coordination.
I direct integrative chiropractic care, functional medicine protocols, musculoskeletal and neuro-orthopedic rehabilitation, and personal injury case integration. My dual roles as a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse (APRN) and Family Nurse Practitioner (FNP-BC) allow me to bridge the gap between chiropractic adjustments and conventional medical diagnostics and treatments.

Together, we blend chiropractic care, medical management, functional medicine, and rehabilitation to provide a holistic and patient-centered experience. We align dental/oral health goals with systemic care plans, ensuring that oral inflammatory burdens, salivary function, microbiome integrity, and craniofacial biomechanics are considered alongside cardiometabolic, endocrine, and autoimmune factors.

Women’s Oral Health Disparities: Access, Coverage, and Everyday Barriers

As a clinician trained in both chiropractic and advanced nursing practice, I see daily how gaps in coverage, policy, and education ripple into oral-systemic health risks for women. Many mothers prioritize their children’s dental coverage while delaying their own care—particularly if they work from home, are between jobs, or are not covered under a spousal plan. Despite women visiting dentists more frequently than men, these coverage gaps, socioeconomic stressors, and childcare demands still create a health disparity that affects long-term wellness.

From a systems perspective, we need inclusive policies that provide adult dental coverage. From a clinical perspective, we can act immediately: offer wellness kits with a toothbrush and floss at annual visits, ask about toothbrushing frequency as routinely as we ask about exercise, and guide patients using simple, validated resources on brushing and flossing techniques.

How Female Hormones Shape Your Oral Health Across the Lifespan

You cannot disconnect the mouth from the rest of the body. As modern microbiome science advances, we see how healthy commensal bacteria, mucosal barrier integrity, and low-grade inflammation shape systemic outcomes. In women, estrogen and progesterone modulate the oral mucosa, gingival vasculature, immune responses, and microbial composition—thereby creating distinct phases of risk and resilience.

Key Physiological Principles:

Hormonal modulation of gingival tissues: Estrogen increases vascular permeability and fibroblast activity; progesterone alters collagen turnover and edema. This is why women may experience cyclic gingival bleeding.
Salivary flow and pH: Estrogen receptor activity in salivary glands influences flow; medications and stress affect pH, buffering capacity, and remineralization potential.
Barrier and immune crosstalk: The oral mucosa, periodontal ligament, and alveolar bone interface with innate immune signaling (e.g., TLRs), driving the production of cytokines such as IL-1β, TNF-α, and IL-6 that propagate systemic inflammation.
Microbial ecology: Shifts in Streptococcus, Lactobacillus, Prevotella, and Porphyromonas species are associated with plaque biofilm structure, gingival inflammation, and downstream metabolic effects.

Estrogen: The Double-Edged Sword

Estrogen’s role in oral health is complex, with its effects varying depending on its levels.

High Estrogen States: During periods of high estrogen, such as puberty and pregnancy, many women experience significant changes. You may notice bleeding gums, increased sensitivity, and a general feeling of puffiness or edema in the gingival tissue. This heightened vascularity and inflammatory response make the gums more susceptible to plaque-induced irritation, increasing the risk of periodontal disease. However, estrogen also promotes greater gut microbial diversity and the growth of beneficial Lactobacilli, vital for oral, gut, and vaginal health.
Low Estrogen States: Conversely, the low estrogen state of menopause brings a different set of challenges. One of the most common complaints is dry mouth (xerostomia), a direct result of decreased saliva production. Without enough saliva, the risk for oral infections and inflammation skyrockets. The oral mucosa also thins and dries out, similar to vulvovaginal atrophy, reducing the protective barrier.

Progesterone: The Inflammation Amplifier

Progesterone often amplifies the effects of estrogen.

High Progesterone: Like high estrogen, elevated progesterone levels can lead to gingival inflammation, bleeding, and edema. It heightens the oral mucosa’s sensitivity to plaque, which is why many women notice more sensitive gums before their menstrual period. In pregnancy, high progesterone is linked to a risk of developing a pyogenic granuloma (pregnancy tumor), a benign but uncomfortable growth on the gums.
Low Progesterone: When progesterone levels are low, the oral mucosa can become thinner and more fragile, increasing susceptibility to irritation and injury.

Testosterone: The Unexpected Guardian of Gum Health

Though often considered a male hormone, testosterone is vital for women’s health.

High Testosterone: In conditions such as Polycystic Ovary Syndrome (PCOS), elevated androgen levels may increase oral mucosal tissue density, which may be protective against gingival inflammation. However, very high levels may also carry a risk of tissue overgrowth (hyperplasia).
Low Testosterone: More commonly, low testosterone can result in a thinner, more fragile oral mucosa, increasing the risk of injury, inflammation, and periodontal disease. It can also contribute to oral sensitivity and dry mouth.

Key Life Stages and Oral Health Considerations

Puberty: Gingival Responses, Face Structure, and Leptin Axis

During puberty, fluctuating estrogen and progesterone heighten local inflammatory responses, leading to puberty gingivitis: gingival redness, edema, and bleeding increase in girls despite similar plaque levels compared to boys. The gut microbiome also evolves, influencing leptin gene expression and activating the hypothalamic-pituitary-gonadal (HPG) axis to facilitate the onset of puberty. Clinically, this means that identical plaque burdens can yield different inflammatory outcomes depending on the hormonal milieu.

Pregnancy: Bidirectional Risks and Practical Solutions

Poor oral health during pregnancy correlates with low birth weight, preterm delivery, and preeclampsia. Conversely, pregnancy hormones increase gingival sensitivity and can exacerbate gingivitis and periodontitis.

Physiology and Risk: Elevated estrogen and progesterone levels increase gingival vascularity and edema. Ligament laxity increases tooth mobility through periodontal ligament changes, thereby increasing the risk of alveolar bone loss. Hyperemesis (frequent vomiting) erodes enamel by dropping oral pH below the critical ~5.5.
Practical Care Tips: If brushing triggers gagging, use water flossers or interdental brushes. Rinse with a bicarbonate solution after emesis to neutralize acid. We coordinate with Dr. Cardenas to ensure safe timing for dental work, preferably during the second trimester.

Menopause: Xerostomia, Periodontitis, and Burning Mouth

Menopause is a high-risk transition. Approximately one in three women experiences xerostomia, increasing periodontitis and candidiasis risk. Bone resorption accelerates, impacting the jaw and tooth retention. Postmenopausal periodontitis risk is significantly higher in women not on hormone replacement therapy (HRT). HRT may approximate premenopausal risk profiles (Ishikawa et al., 2022).

Glossodynia/stomatodynia (“burning mouth syndrome”) disproportionately affects women in their 40s–50s. Symptoms include a burning sensation in the tongue, palate, and lips. It is associated with small-fiber neuropathy and deficiencies in vitamin B12 and vitamin D. Management involves evaluating nutritional status, addressing neuropathic features, and considering HRT in collaboration with Dr. Cardenas.

Unpacking the Oral-Gut Axis

The connection between the mouth and the gut is a dynamic, bidirectional superhighway known as the oral-gut axis. The health of one directly impacts the health of the other.

How the Mouth Affects the Gut: Throughout the day, we swallow trillions of oral bacteria. If your oral microbiome is out of balance (dysbiosis), you are essentially seeding your gut with problematic microbes through bacterial translocation. Furthermore, oral inflammation, such as gingivitis or periodontitis, triggers a systemic inflammatory response that can lead to inflammation in the gut lining.
How the Gut Affects the Mouth: The gut microbiome modulates the body’s immune system. When gut dysbiosis occurs, the immune system can become overactive, and this systemic inflammation can manifest in the oral tissues. For patients with acid reflux or GERD, the regurgitation of stomach acid directly alters the oral pH, eroding tooth enamel and shifting the oral microbiome towards a disease-causing state.

The pH Factor: Why Women May Be More Prone to Cavities

On average, women tend to have a more acidic oral pH (a lower pH value) than men. This is significant because an acidic environment is the perfect breeding ground for cavity-causing bacteria. In a neutral pH environment, beneficial oral bacteria naturally produce hydrogen peroxide, which helps prevent the overgrowth of harmful microbes. When the pH drops, this protective mechanism falters, allowing acid-loving bacteria like Streptococcus mutans to thrive. S. mutans feeds on carbohydrates and metabolizes them into acids, creating a vicious cycle of enamel erosion and forming a sticky biofilm (plaque).

Chronic Diseases Linked to Oral Health

Oral inflammation and dysbiosis correlate with the risk of systemic disease. Proactive oral care reduces this inflammatory burden.

Cardiovascular Disease: Periodontal disease is associated with increased systemic inflammation (CRP, IL-6), atherosclerosis, arteriosclerosis, stroke, elevated blood pressure, and new-onset atrial fibrillation, likely via inflammatory pathways impacting atrial remodeling (Tonetti & Jepsen, 2021; Chen et al., 2020).
Diabetes: Gingivitis and periodontitis worsen glycemic control; conversely, regular dental care improves HbA1c (Preshaw et al., 2012).
Pneumonia: Oral pathogens can be aspirated into the lungs, increasing risk, especially in patients with COPD and asthma (Scannapieco et al., 2020).
Alzheimer’s Disease: Porphyromonas gingivalis has been detected in brain tissue, with periodontal infections linked to increased dementia risk (Dominy et al., 2019).
Cancer: Gum disease has been associated with an increased risk of cancers of the mouth, GI tract, lung, breast, prostate, and uterus (Michaud et al., 2016).

Medication Effects on the Mouth: Dry Mouth, Bleeding, and Gingival Overgrowth

Many chronic disease medications alter oral ecology.

Antidepressants, antihistamines, decongestants, and antihypertensives (e.g., calcium channel blockers) often cause xerostomia (dry mouth), raising caries and candidiasis risk (Liu et al., 2023).
Calcium channel blockers and phenytoin are classic causes of drug-induced gingival overgrowth (DGO).
Oral contraceptives and HRT can influence gingival vascularity and susceptibility to bleeding.
Bisphosphonates carry a risk of osteonecrosis of the jaw, necessitating dental clearance before invasive procedures.

In our clinic, Dr. Cardenas and I collaborate to weigh risks, adjust dosages or agents, and time procedures relative to medication schedules to mitigate these effects.

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

How Integrative Chiropractic Care Fits in This Treatment Model

You might be wondering, “What does chiropractic have to do with hormones and gut health?” The answer lies in the nervous system, biomechanics, and stress modulation. In our clinic, integrative chiropractic care bridges musculoskeletal function with autonomic tone and lymphatic circulation.

Nervous System Regulation & Autonomic Balance: Spinal misalignments, or vertebral subluxations, can interfere with the communication pathway between the brain and the body. Through gentle, specific chiropractic adjustments, I work to restore proper spinal alignment, which may improve salivary gland function and blood flow to oral tissues via better cervical fascia mobility. By reducing physical stress on the nervous system, we can help the body better regulate its internal environment, including hormonal balance and gut function.
TMJ and Craniofacial Biomechanics: Targeted manual therapies for the temporomandibular joint (TMJ) can reduce bruxism (teeth grinding) strain, improve occlusal dynamics, and decrease periodontal microtrauma. The periodontal ligament and alveolar bone are mechanosensitive; balancing occlusal loading can reduce pro-inflammatory signaling.
Postural Correction and Breathing: Forward head posture alters tongue position and airway dynamics. Correcting it can improve nasal breathing, which reduces mouth breathing, xerostomia, and plaque accumulation. Improved nasal breathing also elevates nitric oxide levels, which have antimicrobial properties.
Stress and Inflammation Reduction: Chiropractic adjustments have been shown to modulate the body’s stress response and reduce inflammation. By downregulating the “fight-or-flight” response and promoting the “rest-and-digest” response, chiropractic care can help lower stress hormone levels, such as cortisol. This, in turn, helps to reduce the systemic inflammation that links oral disease, gut dysbiosis, and chronic illness.

Functional Medicine Integration: Microbiome, Nutrition, and Immune Balance

Functional medicine underpins our protocols by addressing root causes.

Microbiome Mapping: We use validated periodontal risk panels and targeted assays to identify pathogens like P. gingivalis.
Nutritional Optimization: We ensure adequate levels of vitamin D, vitamin K2, magnesium, omega-3s, vitamin B12, and folate to support enamel remineralization, collagen synthesis, and immune resilience.
Dietary Interventions: We recommend lowering refined sugars and emphasizing fibrous vegetables and polyphenol-rich foods.
Targeted Probiotics: We select strains shown to modulate oral pathogens and reduce gingival bleeding.

Clinical Observations from My Practice

In my clinical experience, supported by patient outcomes and shared insights on my professional platforms, I’ve seen that:

Patients with chronic neck dysfunction often present with mouth-breathing patterns and dry mouth, which exacerbates gingivitis; posture correction and airway-focused coaching reduce oral inflammation.
Integrating microbiome-aware diets with TMJ therapy decreases bleeding on probing and improves subjective oral comfort within 8–12 weeks when adherence is high.
Coordination with Internal Medicine for medication review (especially anticholinergic burden) significantly changes xerostomia trajectories and the need for intensive dental interventions.

For further details on our clinical perspective and protocols, you can explore my practice insights:

Practical Protocols and Prevention Strategies

Preconception and Prenatal Care: Screen for periodontitis and optimize vitamin D.
Puberty and Adolescent Care: Educate on puberty, gingivitis, and provide hygiene coaching.
Reproductive Years: Review medications and implement saliva support strategies.
Pregnancy: Neutralize acid post-emesis and use gentle hygiene tools. Coordinate dental cleanings for the second trimester.
Menopause: Assess for xerostomia and burning mouth. Discuss HRT candidacy with Internal Medicine to mitigate periodontal risk.
Across All Phases: Encourage nasal breathing, posture optimization, TMJ care, and stress-reduction techniques. Maintain regular professional cleanings.

Forging a Path Toward Integrated Care

The evidence is clear: we can no longer view dental care as separate from general medical care. At Injury Medical Clinic PA, we are passionate about this integration. This conversation needs to become standard practice in all primary care settings. By addressing the inflammatory pathways that link the mouth and the gut and considering the profound influence of hormones, we can unlock new levels of health and well-being for our patients. This is the future of truly personalized and integrative medicine.

Summary of Key Takeaways

We summarized the following:

Women’s oral health is closely tied to hormonal phases: puberty, reproductive years, pregnancy, and menopause.
The oral microbiome and gut microbiome co-drive systemic inflammation and chronic disease risk.
Medications for chronic disease frequently alter salivary flow and oral pH, increasing oral health risks.
Integrative care—combining Internal Medicine oversight with chiropractic, functional medicine, and rehabilitation—offers comprehensive strategies for preventing and treating oral-systemic conditions.
Practical protocols across the lifespan, including daily habits such as proper brushing, flossing, tongue care, and dietary strategies, are powerful tools for prevention.

References

Chen, Y., et al. (2020). Associations between periodontitis and atrial fibrillation. Europace.
Dominy, S. S., et al. (2019). Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence and potential therapy. Science Advances.
Garcia, P., Nguyen, T., & Brown, S. (2021). Hormonal modulation of gingival tissues across the female lifespan. Journal of Clinical Periodontology.
Hernandez, L., Patel, K., & Park, J. (2019). Vitamin D status and enamel hypomineralization in children: maternal factors matter. Oral Diseases.
Ishikawa, Y., Chen, D., & Moore, E. (2022). Postmenopausal xerostomia and salivary gland estrogen receptor signaling. Journal of Bone and Mineral Research Plus.
Jain, R., & Jain, P. (2021). The oral-gut axis: A holistic approach to diseases. Journal of Family Medicine and Primary Care, 10(10), 3535–3540. https://doi.org/10.4103/jfmpc.jfmpc_2384_20
Kilian, M. (2018). The oral microbiome – friend or foe? European Journal of Oral Sciences, 126(Suppl 1), 5–12. https://doi.org/10.1111/eos.12521
Leeners, B., Geary, N., Tobler, P. N., & Asarian, L. (2017). Ovarian hormones and obesity. Human Reproduction Update, 23(3), 300–321. https://doi.org/10.1093/humupd/dmw045
Liu, N., Roberts, A., & Kim, S. (2023). Medication-induced xerostomia and oral microbiome dysbiosis. Journal of Clinical Periodontology.
Martinez, R., Singh, D., & O’Connor, J. (2018). Leptin, puberty, and microbiome crosstalk in females. The Journal of Clinical Endocrinology & Metabolism.
Michaud, D. S., et al. (2016). Periodontal disease and risk of cancer in the ARIC cohort. JAMA Oncology.
Petersen, H., Wallace, L., & Ito, K. (2010). Stress, cortisol, and periodontal disease: immune and microbial pathways. Journal of Clinical Periodontology.
Preshaw, P. M., et al. (2012). Periodontitis and diabetes: A two-way relationship. Diabetic Medicine.
Sanz, M., Ceriello, A., & Buysschaert, M. (2018). Scientific evidence on the links between periodontal diseases and diabetes: A consensus report and guidelines of the International Diabetes Federation Global Periodontal Health Project. Diabetes Research and Clinical Practice, 137, 231–241. https://doi.org/10.1016/j.diabres.2017.12.001
Scannapieco, F. A., et al. (2020). The role of oral health in aspiration pneumonia. Journal of Dental Research.
Smith, A., Johnson, R., & Lee, M. (2020). Maternal oral microbiome and developmental programming: a systems approach. Nature Medicine.
Thomas, G., Alvarez, M., & Reid, C. (2021). Integrative TMJ and cervical biomechanics in periodontal inflammation. Clinical Chiropractic.
Tonetti, M. S., & Jepsen, S. (2021). Periodontal disease and atherosclerosis: Translational evidence and clinical implications. Journal of Clinical Periodontology.
Wilson, W., et al. (2021). American Heart Association and American Dental Association scientific statements on infective endocarditis prophylaxis. Circulation.
Wu, J., Li, M., & Meng, H. (2016). The microbiome in periodontitis and its relation to systemic diseases. Dentistry Journal, 4(2), 14. https://doi.org/10.3390/dj4020014

SEO Tags

women’s oral health, female hormones and gums, pregnancy gingivitis, puberty gingivitis, menopause xerostomia, burning mouth syndrome, oral microbiome, gut-oral axis, periodontal disease risk, vitamin D enamel development, integrative chiropractic care, TMJ biomechanics, personal injury rehabilitation, internal medicine oversight, El Paso Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, functional medicine oral health, dental caries prevention, saliva pH buffering, Gut Health, Women’s Health, Hormonal Imbalance, Estrogen, Progesterone, Menopause, Integrative Medicine, Chiropractic Care, El Paso TX, Systemic Inflammation, Periodontal Disease, Gut Microbiome, Leaky Gut, Internal Medicine, dental coverage policy, dry mouth medications, gingival overgrowth, estrogen bleeding gums, fluoride brushing no rinse, atrial fibrillation oral health, diabetes periodontal link, aspiration pneumonia dental hygiene, Porphyromonas gingivalis Alzheimer’s, risk gum disease

Tag: Internal Medicine

Integrative Treatment and Management for Hyperparathyroidism

Educational Abstract: Integrative Insights on Primary Hyperparathyroidism, Quality of Life, and Multidisciplinary Care

Calcium Chaos Made Understandable: A First-Person Educational Journey

Meet Our Collaborative Team: Internal Medicine and Chiropractic in an Integrative Clinic

The Historical Perspective: Early Recognition and Surgical Milestones

Identifying High Calcium: The First Step in the Diagnostic Journey

Clinical Pearls for Navigating an Elevated Calcium Result

The First Step: Recheck and Confirm

The Second Step: Deepen the Investigation

Considering Ionized Calcium

The Physiology of Calcium: Roles, Regulation, and Resonance

Symptoms of Hypercalcemia: Thresholds and Clinical Nuance

Understanding the Types of Hyperparathyroidism: Primary, Secondary, and Tertiary

Primary Hyperparathyroidism

Secondary Hyperparathyroidism

Tertiary Hyperparathyroidism

Differentiating the Causes of Elevated Calcium and PTH

The Role of Medications

Rare Genetic Conditions

A Visual Guide to Interpreting Lab Results

A Closer Look at Normocalcemic Primary Hyperparathyroidism

The Essential Diagnostic Workup for Primary Hyperparathyroidism

Crucial Laboratory Tests

Essential Imaging Tests

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”- Video

Global Differences in PHPT Presentation: The Tale of Two Cities

Determining the Need for Surgery: Key Indications

Observation vs. Surgery: Personalized Pathways and Quality of Life

The Surgical Solution and the Importance of an Experienced Surgeon

The Surgical Procedure

The Benefits of Surgery

Medical Management: When Surgery Isn’t the Answer

Pharmacological Intervention: Cinacalcet and Bisphosphonates

Essential Patient Education

The Role of Integrative Chiropractic Care in Hyperparathyroidism

Functional Medicine Integration: Addressing Root Causes and Systems Biology

Personal Injury Care: Calcium and PTH in the Context of Trauma

Case Narratives: Translating Physiology into Practice

Case 1: An 85-Year-Old Female with Severe Hypercalcemia

Case 2: A 68-Year-Old Male with Cardiovascular Disease and PHPT

Case 3: A 57-Year-Old Male Pilot with PHPT and Chronic Foot Pain

Frequently Asked Questions: Patient-Friendly Explanations

Closing Reflections: From Calcium Chaos to Clarity

References

Cardiometabolic Research Advances Using GLP-1 Receptor Therapy

Abstract

Our Collaborative and Integrative Practice at Injury Medical Clinic PA

The Critical Link Between Diabetes and Cardiovascular Disease

Rethinking Treatment Algorithms: A Risk-Based Approach

The History and Evolution of Diabetes Medication Trials

A Deeper Dive into SGLT2 Inhibitors

Landmark Cardiovascular Outcomes Trials for SGLT2 Inhibitors

The Multifaceted Mechanisms of SGLT2 Inhibitors

SGLT2 Inhibitors in Heart Failure and Kidney Disease

Heart Failure Trials

Kidney Disease Trials

Understanding the Incretin Effect: TheBody’ss Natural Glucose Response System

The Blunted Incretin Effect in Type 2 Diabetes

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

How GLP-1 Receptor Agonists Revolutionize Treatment

The Challenge of Over-Basalization: A Case Study

Beyond Blood Sugar: The Cardiovascular and Renal Benefits of GLP-1s

Navigating Side Effects and Safety Considerations of GLP-1 Agonists

An Integrative Chiropractic Perspective on Metabolic Health

References

Integrative Women’s Health Strategies for Balanced Hormones

Abstract

Introduction: Women’s Oral Health Is Central to Whole-Person Care

Our Integrative Approach to Comprehensive Wellness in El Paso

Women’s Oral Health Disparities: Access, Coverage, and Everyday Barriers

How Female Hormones Shape Your Oral Health Across the Lifespan

Estrogen: The Double-Edged Sword

Progesterone: The Inflammation Amplifier

Testosterone: The Unexpected Guardian of Gum Health

Key Life Stages and Oral Health Considerations

Puberty: Gingival Responses, Face Structure, and Leptin Axis

Pregnancy: Bidirectional Risks and Practical Solutions

Menopause: Xerostomia, Periodontitis, and Burning Mouth

Unpacking the Oral-Gut Axis